Frontiers in Pharmacology
January 28, 2020
Esther Papaseit, Clara Pérez-mañá, Elizabeth B. de Sousa Fernandes Perna et al.
27 citations
Combining mephedrone with alcohol amplifies cardiovascular effects and intensifies euphoria and well-being compared to either drug alone, while mephedrone reduces the sedative effects of alcohol. In a double-blind, placebo-controlled trial with 11 male volunteers, the combination increased blood pressure, heart rate, and subjective feelings of euphoria. Mephedrone alone and alcohol alone were also tested. The results suggest that the abuse liability of mephedrone is greater when taken with alcohol, similar to other psychostimulants like amphetamines and MDMA.
Frontiers in pharmacology
January 1, 2025
Georgina De la Rosa, Esther Papaseit, Olga Hladun et al.
7 citations
Alpha-pyrrolidinopentiophenone (α-PVP), a synthetic cathinone similar to MDPV and cocaine, produces rapid-onset psychostimulant and empathogenic effects after a single intranasal dose. In nine participants with prior psychostimulant use, 10 mg or 20 mg of α-PVP caused an acute increase in blood pressure and heart rate that peaked 40 minutes after administration. Subjective effects appeared quickly and resolved within 3 to 5 hours. The drug's psychostimulant properties resembled those of cocaine, and its empathogenic effects were similar to those of MDMA and other cathinones like methylone.
Handbook of Substance Misuse and Addictions
January 1, 2022
Esther Papaseit, Magí Farré, Clara Pérez-mañá
Public health efforts must balance preventing illicit drug use with ensuring access to medicines that have abuse potential. Drug interactions for drugs of abuse, unlike those for medicines, are largely underexplored and not part of clinical routine. MDMA (ecstasy, molly) exemplifies this: it is a popular recreational psychostimulant and is being evaluated for treating post-traumatic stress disorder. Understanding inter- and intraindividual factors, modulation factors, and potential interactions is crucial to assess intoxication risk for both recreational users and patients in future MDMA-assisted therapy.